Landmark Study Challenges Decades of Statin Fears, Paving Way for Wider Use
Table of Contents
A major new analysis published Thursday in The Lancet is poised to reshape perceptions of statins, the widely prescribed cholesterol-lowering drugs, by debunking long-held concerns about their side effects. The research reveals that the vast majority of adverse health outcomes previously linked to statins – 62 out of 66 – are not supported by reliable evidence, potentially opening the door for millions more to benefit from cardiovascular disease prevention.
For years, a lengthy list of potential side effects detailed in package inserts and discussed in doctor’s offices has created barriers to statin use. Many patients, and even some physicians, have been hesitant to prescribe or take the medications, despite their proven ability to reduce the risk of heart attack and stroke. This reluctance has persisted even as generic versions of statins remain remarkably affordable, costing as little as $40 per year in the United States.
The new meta-analysis, a 10-year review of 19 large randomized clinical trials involving over 122,000 people conducted by the Cholesterol Treatment Trialists’ Collaboration, found strong evidence for only four potential concerns: changes in liver tests, minor liver abnormalities, urine changes, and tissue swelling. However, researchers characterized these risks as “very small.”
“Ongoing confusion and concern, not just in patients, but also in many doctors regarding potential statin side effects, mean that many people are not willing to start statins, or have stopped them, even if they’re at high risk of having either a first or recurrent heart attack or stroke and may derive really significant benefit from them,” explained Christina Reith, associate professor at Oxford Population Health and lead author of the study, during a media briefing Tuesday. “What we found is there’s no significant excess risk with statins for almost all the conditions listed in statin packaging as potential side effects.”
Statins: A Cornerstone of Preventive Cardiology
Statins are considered a cornerstone of preventive cardiology, effectively lowering levels of LDL, or “bad” cholesterol, by as much as 50%. This reduction prevents the buildup of plaque in blood vessels, ultimately decreasing the risk of heart attacks and strokes by 25%. The study’s findings suggest that the benefits of statins far outweigh the minimal risks.
The research also supports a potential shift in when statins are prescribed. Current guidelines typically focus on a 10-year risk assessment. However, a separate study published last month in Circulation: Population Health and Outcomes analyzed risk over a 30-year period using PREVENT equations. This longer-term analysis revealed that 9% of individuals aged 30 to 59 have an estimated 30-year risk of heart attack or stroke of 20% or greater – a figure that could translate to 2.5 million more adults being advised to take statins. An additional 44% were found to have an intermediate risk, ranging from 7.5% to 19.9%.
New Guidelines Expected to Expand Statin Eligibility
The American College of Cardiology and the American Heart Association are expected to release updated guidelines in the second quarter of this year, incorporating these new 30-year risk assessments. These changes could significantly broaden the number of Americans eligible for statin therapy.
While primary prevention typically emphasizes diet and exercise, the new data highlight a critical gap in guidance for individuals with high blood pressure, high cholesterol, or a family history of heart disease. “There has been a gap in data to guide who might benefit from starting medication earlier and who might be safe delaying that conversation for 20 years,” said Timothy Anderson, lead author of the Circulation paper and a primary care physician at the University of Pittsburgh Medical Center.
Anderson emphasized the consistent benefits of statins, stating, “It’s fairly clear that statins consistently reduce folks’ relative risk of a heart attack or stroke by about a quarter.” The question now, he posited, is whether to initiate treatment at age 40 or wait until the 10-year risk increases.
Addressing Patient Concerns and Building Trust
The four side effects identified as potentially linked to statins – liver test changes, minor liver abnormalities, urine changes, and tissue swelling – are real and require consideration, the Lancet authors acknowledged. The rare but serious condition of rhabdomyolysis, involving muscle tissue breakdown, would necessitate switching to alternative cholesterol-lowering agents. Less severe muscle symptoms occur in approximately 1% of patients.
An increase in blood glucose levels was also observed, primarily in individuals already close to the diagnostic threshold for type 2 diabetes. However, Reith noted that the benefits of statins outweigh the risks, even for those with existing diabetes.
The authors recognize the broader challenge of building trust in medical interventions, particularly in the wake of growing skepticism fueled by events like the Covid-19 pandemic. “I think that really is a larger trust-in-the-medical community sort of conversation,” Anderson said. “As patients get to know their doctors, they often develop trust in that individual even if they have concerns about other aspects of society and the health care system. So the best thing we can do is get to know our patients well, and ideally, develop that trust and that bond with them.”
The findings from The Lancet offer clinicians valuable talking points to address patient concerns about uncommon side effects. However, experts believe that fostering a strong doctor-patient relationship remains paramount to overcoming broader hesitancy towards long-term medications.
